The present study reveals that icotinib and BDMC combination suppress migration and invasion in TKI-resistant NSCLC cells through the induction of HLJ1/E-cadherin and the inhibition of MMP-2/MMP-9 expression, which depend on ROS generation and autophagy induction. Here, MMP2 is linked to non-small cell lung carcinoma.